spot_img
Saturday, August 13, 2022
More
    HomeHealthCMS decision on Alzheimer's drug could shock state Medicaid programs

    CMS decision on Alzheimer’s drug could shock state Medicaid programs

    -



    Shortly after the controversial Biogen drug Alzheimer’s was accredited within the U.S. final yr, a pair of state Medicaid administrators tried to ring alarm bells.

    In a terse letter, they implored the Biden administration to make sure Medicare covers the drugs, regardless of restricted effectiveness and a $56,000 price ticket. Their reasoning was easy. If Medicare reacted to the extremely questionable approval by withholding or proscribing protection, Medicaid can be left holding the proverbial bag, as a result of by regulation it should cowl medication endorsed by the Meals and Drug Administration.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,435FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts